Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with reduced-dose Neoral vs mycophenolate mofetil with standard-dose Neoral in de novo renal transplant recipients
jRCT2080220571Phase 3
- Sponsor
- Novartis
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of everolimus in kidney transplant immunosuppression (2 arms), sponsored by Novartis.
02
Drugs
everolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on jRCT2080220571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220571.